Cannatrek Medical ships it’s first batch of MC products to Australian patients

Cannatrek Medical ships it’s first batch of MC products to Australian patients

MELBOURNE, Australia, 26th November 2018/- Cannatrek Ltd (“Cannatrek” or the “Company”) announced today that its wholly owned subsidiary, Cannatrek Medical Pty Ltd, processed its first medicinal cannabis prescriptions after GPs chose Cannatrek’s products, as a medicine to treat a variety of indications under the SAS (Special Access Scheme) scheme.

After nearly 100 days since the 48-access portal was launched by the TGA (www.sas.tga.gov.au), patient access has increased many fold. Today there are about seven scripts per day being approved by the TGA, under the scheme and Cannatrek Medical is positioning itself to be Australia’s leading and lowest cost provider of imported medicinal cannabis products to Australian consumers.

Prescribers and patients can now register at www.cannatrek.com

To access further information regarding clinical research, medical cannabis products availability, prices and access pathways.